Drug profile · INN
anifrolimab-fnia
SAPHNELO
anifrolimab-fnia (SAPHNELO) is a interferon-alpha/beta receptor alpha chain antagonist. Route of administration: single-use. Current US regulatory status: approved.
Drug details — anifrolimab-fnia
- US status
- approved
- Class
- —
- Route
- SINGLE-USE
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
anifrolimab-fnia (SAPHNELO) is a interferon-alpha/beta receptor alpha chain antagonist. Route of administration: single-use. Current US regulatory status: approved.
Key facts
Mechanism of action
Interferon-alpha/beta receptor alpha chain antagonist
Primary target: Interferon alpha/beta receptor 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is anifrolimab-fnia?
anifrolimab-fnia (SAPHNELO) is a interferon-alpha/beta receptor alpha chain antagonist. Route of administration: single-use. Current US regulatory status: approved.
What is the brand name for anifrolimab-fnia?
SAPHNELO is a marketed brand name for anifrolimab-fnia. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of anifrolimab-fnia?
anifrolimab-fnia has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.